TARDBP and Alzheimer disease: To test our hypothesis that starting in 2019 neuropathology cores of ADCs may have begun foregoing neocortical TDP-43 assessment if no inclusions were found in the hippocampus (in response to LATE-NC staging), we compared the rate of availability of neocortical TDP-43 assessment by presence of TDP-43 in the hippocampus in those with a presumptive etiologic diagnosis of AD (most relevant to LATE-NC), both for participants who died before, and participants who died during or after, 2019.